Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia.
Publication/Presentation Date
1-1-2024
Abstract
Although both clinical data and animal models suggest cardiovascular benefits following administration of Dipeptidyl Peptidase 4 (DPP-4) inhibitors, the underlying mechanisms remain unclear. We therefore sought to evaluate the effect of the DPP-4 inhibitor sitagliptin on myocardial fibrosis, and insulin signaling in chronic myocardial ischemia using a swine model. An ameroid constrictor placement on the left coronary circumflex artery of thirteen Yorkshire swine to model chronic myocardial ischemia. After two weeks of recovery, swine were assigned to one of two groups: control (CON, n = 8), or sitagliptin 100mg daily (SIT, n = 5). After 5 weeks of treatment, the swine underwent terminal harvest with collection of myocardial tissue. Fibrosis was quantified using Masson's trichrome. Protein expression was quantified by Immunoblotting. Trichrome stain demonstrated a significant decrease in perivascular and interstitial fibrosis in the SIT group relative to CON (all p
Volume
19
Issue
7
First Page
0307922
Last Page
0307922
ISSN
1932-6203
Published In/Presented At
Harris, D. D., Sabe, S. A., Broadwin, M., Stone, C., Bellam, K., Malhotra, A., Abid, M. R., & Sellke, F. W. (2024). Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia. PloS one, 19(7), e0307922. https://doi.org/10.1371/journal.pone.0307922
Disciplines
Medicine and Health Sciences
PubMedID
39074126
Department(s)
Fellows and Residents
Document Type
Article